Eli Lilly and Company (LLY) Position Held by Timber Creek Capital Management LLC
Timber Creek Capital Management LLC maintained its position in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 56,611 shares of the company’s stock at the end of the second quarter. Eli Lilly and makes up approximately 3.6% of Timber Creek Capital Management LLC’s holdings, making the stock its 6th biggest holding. Timber Creek Capital Management LLC’s holdings in Eli Lilly and were worth $4,761,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of LLY. Acrospire Investment Management LLC grew its holdings in Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares in the last quarter. Point72 Asia Hong Kong Ltd grew its holdings in Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares in the last quarter. Shine Investment Advisory Services Inc. purchased a new position in Eli Lilly and during the 2nd quarter valued at about $148,000. Cornerstone Advisors Inc. grew its holdings in Eli Lilly and by 18.4% during the 2nd quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock valued at $166,000 after buying an additional 313 shares in the last quarter. Finally, American National Bank grew its holdings in Eli Lilly and by 5.2% during the 2nd quarter. American National Bank now owns 2,088 shares of the company’s stock valued at $172,000 after buying an additional 104 shares in the last quarter. 75.48% of the stock is owned by institutional investors and hedge funds.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 190,000 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $82.53, for a total value of $15,680,700.00. Following the completion of the sale, the insider now owns 123,682,287 shares in the company, valued at $10,207,499,146.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders sold 772,003 shares of company stock valued at $64,837,441 in the last quarter. Corporate insiders own 0.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/17/eli-lilly-and-company-lly-position-held-by-timber-creek-capital-management-llc.html.
Shares of Eli Lilly and Company (LLY) opened at $83.44 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $89.09. The firm has a market capitalization of $90,499.01, a P/E ratio of 20.09, a price-to-earnings-growth ratio of 1.81 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the previous year, the company posted $0.88 earnings per share. The business’s revenue was up 9.0% on a year-over-year basis. equities research analysts forecast that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.49%. Eli Lilly and’s payout ratio is currently 98.58%.
LLY has been the subject of several recent analyst reports. UBS AG lowered Eli Lilly and to a “hold” rating and set a $85.00 price objective for the company. in a report on Wednesday, July 26th. BMO Capital Markets reissued a “sell” rating and set a $71.00 price objective on shares of Eli Lilly and in a report on Thursday, September 28th. Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the stock a “hold” rating in a report on Friday, October 6th. Piper Jaffray Companies reissued a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a report on Friday, October 13th. Finally, Berenberg Bank reissued a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $89.76.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.